Mark A. Emalfarb is the Founder and Chief Executive Officer of Dyadic International, Inc. (Nasdaq: DYAI), a U.S.- and EU-based global biotechnology company advancing its patented and proprietary C1 gene expression platform to enable faster, more efficient, and more affordable development and manufacturing of vaccines, biologics, and other biopharmaceutical products. An inventor on more than 25 U.S. and foreign biotechnology patents and applications, Mr. Emalfarb has guided Dyadic through multiple transformational milestones, including the sale of its industrial biotechnology business to DuPont for $75 million, which positioned the company squarely within human and animal health.
Under his leadership, Dyadic has built collaborations with leading pharmaceutical, biotech, academic, and government organizations worldwide. These include the U.S. Frederick National Laboratory/Vaccine Research Center (NIAID/NIH), the Laboratory of Malaria Immunology and Vaccinology (NIAID), the Bill & Melinda Gates Foundation, CEPI, the EU Zoonosis Anticipation and Preparedness Initiative (ZAPI), the EU Vaccine Hub/Fondazione Biotecnopolo di Siena, the Israel Institute for Biological Research (IIBR), and others. These partnerships support the advancement of the C1 protein production platform and accelerate the development of next-generation vaccines and biologics.
Mr. Emalfarb is also a former member of the University of Iowa Hawkeyes NCAA Championship Wrestling Teams.